Oncology and Hematology

369-384 of 663

• 

  RestartResume

  Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR

  RestartResume

  Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR

  GI Insights

  Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR

  Peter Buch, MD, FACG, AGAF, FACP; Vivek Kaul, MD

  • 

    

    Peter Buch, MD, FACG, AGAF, FACP

  • 

    

    Vivek Kaul, MD

• 

  RestartResume

  Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia

  RestartResume

  Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia

  Project Oncology®

  Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia

• 

  RestartResume

  Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions 

  RestartResume

  Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions 

  Global Oncology Academy

  Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions 

• 

  RestartResume

  Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges

  RestartResume

  Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges

  Project Oncology®

  Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges

  Adrienne Waks, MD

  • 

    

    Adrienne Waks, MD

• 

  RestartResume

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  RestartResume

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  MinuteCE®

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  RestartResume

  Management of HER2-Low MBC Following First-Line Disease Progression

  MinuteCE®

  Management of HER2-Low MBC Following First-Line Disease Progression

  Peter Schmid, FRCP, MD, PhD

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  RestartResume

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  MinuteCE®

  First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study   

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  RestartResume

  Emerging Treatment Approaches for EBC

  RestartResume

  Emerging Treatment Approaches for EBC

  MinuteCE®

  Emerging Treatment Approaches for EBC

  William J. Gradishar, MD

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  1.50 program credits

• 

  RestartResume

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  RestartResume

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  MinuteCE®

  The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?  

  Sara Lonardi, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  1.25 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers

  Sara Lonardi, MD; Aparna R. Parikh, MD

  1.25 credits 10 episodes

  • 

    

    Sara Lonardi, MD

  • 

    

    Aparna R. Parikh, MD

  • 

    

    Alan Venook, MD

  1.25 credits 10 episodes

• 

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  RestartResume

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  MinuteCE®

  Expert Viewpoint: Optimizing Breast Cancer Treatment  

  William J. Gradishar, MD; Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• 

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  RestartResume

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  MinuteCE®

  Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  RestartResume

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  MinuteCE®

  Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  RestartResume

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  MinuteCE®

  Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  RestartResume

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  MinuteCE®

  Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

  Sara Lonardi, MD; Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Sara Lonardi, MD

  • 

    

    Aparna R. Parikh, MD

  • 

    

    Alan Venook, MD

  1.25 program credits

• 

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  MinuteCE®

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• Previous
• 1
• 2
• …
• 22
• 23
• 24
• 25
• 26
• …
• 41
• 42
• Next